US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles
What a blast to work at NASA. Space agency is sky
WASHINGTON (AP) — Exploring the cosmos makes for happy employees, federal workers like to work from2024-05-22NZ defence officials began pitching the benefits of joining AUKUS months ago
US President Joe Biden (R) meets with Australian Prime Minister Anthony Albanese (L) during the AUKU2024-05-22'It's a deliberate strategy to erase us' – Whanganui iwi prepare for national hui
Whanganui iwi leader Ken Mair. Photo: LDR / Moana Ellis2024-05-22In pictures: 2024 Rātana celebrations
Winston Peters, Christopher Luxon and Shane Jones at Rātana Pā, January 2024. Photo: Angus Dreaver /2024-05-22Key evidence in the 'burking' murder trial was 'hidden' from defence lawyers
Key evidence which undermined the police case against a man convicted of the so-called 'burking' mur2024-05-22How the New Zealand Falcons are tackling stigma against LGBT people in sports
The touch team practicing at Western Park, Ponsonby. Photo: RNZ / Samuel Robinson2024-05-22
atest comment